gdc

Newsworthy

FDA NewsLeukemiaNewsworthy
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
Erleada First Drug Approved for Patients with Nonmetastatic Prostate Cancer
FDA NewsNewsworthyProstate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer.
Verzenio Approved as Initial Treatment for Metastatic Breast Cancer
Breast CancerFDA NewsNewsworthy
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Page 1 of 5
Results 1 - 10 of 50

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country